Back to School: How biopharma can reboot drug development. Access exclusive analysis here

MedImmune's appetite for truffles

MedImmune Inc.'s biggest deals - the acquisitions of U.S. Bioscience Inc. and Aviron - were been geared toward growing its top line. But in the past year the company has signed four smaller deals aimed at growing its pipeline without adding a lot

Read the full 434 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers